Pure Global

Effects of PSAPs on Speech Processing - Trial NCT05076045

Access comprehensive clinical trial information for NCT05076045 through Pure Global AI's free database. This phase not specified trial is sponsored by Rotman Research Institute at Baycrest and is currently Recruiting. The study focuses on Hearing Loss, Age-Related. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
Device Trial
NCT05076045
Recruiting
Device Trial
device
Trial Details
ClinicalTrials.gov โ€ข NCT05076045
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Effects of PSAPs on Speech Processing
Immediate Effects of Personal Sound Amplification Products on Speech Processing

Study Focus

Hearing Loss, Age-Related

Personal sound amplification products

Interventional

device

Sponsor & Location

Rotman Research Institute at Baycrest

Toronto, Canada

Timeline & Enrollment

N/A

Mar 01, 2022

Aug 30, 2023

100 participants

Primary Outcome

Difference in EEG measure of wave amplitude with and without PSAPs,Difference in EEG measure of wave latency with and without PSAPs,Difference in EEG measure of wave oscillations with and without PSAPs,Difference in EEG measure of connectivity strength with and without PSAPs,Difference in the percentage of correct responses with and without PSAPs,Difference in reaction time with and without PSAPs,Difference in sensitivity with and without PSAPs,Difference in criterion with and without PSAPs

Summary

Mild to moderate hearing loss remains undertreated, largely because of the high cost of
 hearing aids. A promising and much less expensive alternative is the use of personal sound
 amplification products (PSAPs), which are electronic, portable, over-the-counter devices that
 amplify sound. Studies have shown that the use of PSAPs provides significant hearing benefits
 and improves the quality of life for older adults with mild to moderate hearing loss.
 However, there is insufficient data to determine the impact of PSAPs use on speech processing
 in the brain.
 
 The purpose of this study is to use electroencephalography (EEG) measurements to assess the
 neurobiological and behavioral effects of PSAPs on speech perception in noise in individuals
 with mild to moderate hearing loss.
 
 The investigators expect that the PSAPs use will result in an immediate improvement in the
 ability to perceive speech-in-noise, supporting that these hearing devices may be a means of
 restoring communication skills in people with mild to moderate hearing loss. Behavioral
 benefits will be associated with increased brain activity in auditory regions and
 connectivity between auditory and speech regions in the brain.

ICD-10 Classifications

Other hearing loss
Hearing loss, unspecified
Other specified hearing loss
Ototoxic hearing loss
Sudden idiopathic hearing loss

Data Source

ClinicalTrials.gov

NCT05076045

Device Trial